APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sickle Cell Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Sickle Cell Disease Drug Market Analysis and Forecast 2026-2032

19 December 2025201 pages

Choose your research edition.

Industry ResearchSickle Cell Disease Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Sickle Cell Disease Drug Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Sickle Cell Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sickle Cell Disease Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Sickle Cell Disease Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Sickle Cell Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Sickle Cell Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Sickle Cell Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Sickle Cell Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Sickle Cell Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Sickle Cell Disease Drug include Global Blood Therapeutics Inc, Gilead Sciences Inc, Genethon SA, Gamida Cell Ltd, Errant Gene Therapeutics LLC, Editas Medicine Inc, Daiichi Sankyo Co Ltd, CSL Ltd and CRISPR Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Sickle Cell Disease Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Sickle Cell Disease Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Sickle Cell Disease Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Sickle Cell Disease Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Sickle Cell Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Sickle Cell Disease Drug sales, projected growth trends, production technology, application and end-user industry.

Sickle Cell Disease Drug Segment by Company

Global Blood Therapeutics Inc

Gilead Sciences Inc

Genethon SA

Gamida Cell Ltd

Errant Gene Therapeutics LLC

Editas Medicine Inc

Daiichi Sankyo Co Ltd

CSL Ltd

CRISPR Therapeutics

Calimmune Inc

Bristol-Myers Squibb Co

bluebird bio Inc

Bioverativ Inc

Bio Products Laboratory Ltd

ArQule Inc

Annexin Pharmaceuticals AB

Angiocrine Bioscience Inc

Addmedica SAS

Acceleron Pharma Inc

Sickle Cell Disease Drug Segment by Type

CAL-H

DRX-194

CTX-001

BIVV-003

ARQ-092

Others

Sickle Cell Disease Drug Segment by Application

Hospital

Clinic

Others

Sickle Cell Disease Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Sickle Cell Disease Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Sickle Cell Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sickle Cell Disease Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Sickle Cell Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CAL-H Major Manufacturers Table 3. DRX-194 Major Manufacturers Table 4. CTX-001 Major Manufacturers Table 5. BIVV-003 Major Manufacturers Table 6. ARQ-092 Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Sickle Cell Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Major Manufacturers Table 10. Clinic Major Manufacturers Table 11. Others Major Manufacturers Table 12. Sickle Cell Disease Drug Industry Trends Table 13. Sickle Cell Disease Drug Industry Drivers Table 14. Sickle Cell Disease Drug Industry Opportunities and Challenges Table 15. Sickle Cell Disease Drug Industry Restraints Table 16. Global Sickle Cell Disease Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Sickle Cell Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Sickle Cell Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Sickle Cell Disease Drug Revenue Market Share by Region (2021-2026) Table 20. Global Sickle Cell Disease Drug Revenue Market Share by Region (2027-2032) Table 21. Global Sickle Cell Disease Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global Sickle Cell Disease Drug Sales by Region (2021-2026) & (K Units) Table 23. Global Sickle Cell Disease Drug Sales by Region (2027-2032) & (K Units) Table 24. Global Sickle Cell Disease Drug Sales Market Share by Region (2021-2026) Table 25. Global Sickle Cell Disease Drug Sales Market Share by Region (2027-2032) Table 26. Global Sickle Cell Disease Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Sickle Cell Disease Drug Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Sickle Cell Disease Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Sickle Cell Disease Drug Sales Market Share by Manufacturers (2021-2026) Table 30. Global Sickle Cell Disease Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Sickle Cell Disease Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Sickle Cell Disease Drug Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Sickle Cell Disease Drug Manufacturers, Product Type & Application Table 34. Global Sickle Cell Disease Drug Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Sickle Cell Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Sickle Cell Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Sickle Cell Disease Drug Revenue Market Share by Type (2021-2026) Table 41. Global Sickle Cell Disease Drug Revenue Market Share by Type (2027-2032) Table 42. Global Sickle Cell Disease Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units) Table 44. Global Sickle Cell Disease Drug Sales by Type (2027-2032) & (K Units) Table 45. Global Sickle Cell Disease Drug Sales Market Share by Type (2021-2026) Table 46. Global Sickle Cell Disease Drug Sales Market Share by Type (2027-2032) Table 47. Global Sickle Cell Disease Drug Price by Type (2021-2026) & (US$/Unit) Table 48. Global Sickle Cell Disease Drug Price by Type (2027-2032) & (US$/Unit) Table 49. Global Sickle Cell Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Sickle Cell Disease Drug Revenue Market Share by Application (2021-2026) Table 53. Global Sickle Cell Disease Drug Revenue Market Share by Application (2027-2032) Table 54. Global Sickle Cell Disease Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units) Table 56. Global Sickle Cell Disease Drug Sales by Application (2027-2032) & (K Units) Table 57. Global Sickle Cell Disease Drug Sales Market Share by Application (2021-2026) Table 58. Global Sickle Cell Disease Drug Sales Market Share by Application (2027-2032) Table 59. Global Sickle Cell Disease Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Sickle Cell Disease Drug Price by Application (2027-2032) & (US$/Unit) Table 61. Global Blood Therapeutics Inc Company Information Table 62. Global Blood Therapeutics Inc Business Overview Table 63. Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolio Table 65. Global Blood Therapeutics Inc Recent Development Table 66. Gilead Sciences Inc Company Information Table 67. Gilead Sciences Inc Business Overview Table 68. Gilead Sciences Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolio Table 70. Gilead Sciences Inc Recent Development Table 71. Genethon SA Company Information Table 72. Genethon SA Business Overview Table 73. Genethon SA Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Genethon SA Sickle Cell Disease Drug Product Portfolio Table 75. Genethon SA Recent Development Table 76. Gamida Cell Ltd Company Information Table 77. Gamida Cell Ltd Business Overview Table 78. Gamida Cell Ltd Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolio Table 80. Gamida Cell Ltd Recent Development Table 81. Errant Gene Therapeutics LLC Company Information Table 82. Errant Gene Therapeutics LLC Business Overview Table 83. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolio Table 85. Errant Gene Therapeutics LLC Recent Development Table 86. Editas Medicine Inc Company Information Table 87. Editas Medicine Inc Business Overview Table 88. Editas Medicine Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Editas Medicine Inc Sickle Cell Disease Drug Product Portfolio Table 90. Editas Medicine Inc Recent Development Table 91. Daiichi Sankyo Co Ltd Company Information Table 92. Daiichi Sankyo Co Ltd Business Overview Table 93. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolio Table 95. Daiichi Sankyo Co Ltd Recent Development Table 96. CSL Ltd Company Information Table 97. CSL Ltd Business Overview Table 98. CSL Ltd Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. CSL Ltd Sickle Cell Disease Drug Product Portfolio Table 100. CSL Ltd Recent Development Table 101. CRISPR Therapeutics Company Information Table 102. CRISPR Therapeutics Business Overview Table 103. CRISPR Therapeutics Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolio Table 105. CRISPR Therapeutics Recent Development Table 106. Calimmune Inc Company Information Table 107. Calimmune Inc Business Overview Table 108. Calimmune Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Calimmune Inc Sickle Cell Disease Drug Product Portfolio Table 110. Calimmune Inc Recent Development Table 111. Bristol-Myers Squibb Co Company Information Table 112. Bristol-Myers Squibb Co Business Overview Table 113. Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolio Table 115. Bristol-Myers Squibb Co Recent Development Table 116. bluebird bio Inc Company Information Table 117. bluebird bio Inc Business Overview Table 118. bluebird bio Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. bluebird bio Inc Sickle Cell Disease Drug Product Portfolio Table 120. bluebird bio Inc Recent Development Table 121. Bioverativ Inc Company Information Table 122. Bioverativ Inc Business Overview Table 123. Bioverativ Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Bioverativ Inc Sickle Cell Disease Drug Product Portfolio Table 125. Bioverativ Inc Recent Development Table 126. Bio Products Laboratory Ltd Company Information Table 127. Bio Products Laboratory Ltd Business Overview Table 128. Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolio Table 130. Bio Products Laboratory Ltd Recent Development Table 131. ArQule Inc Company Information Table 132. ArQule Inc Business Overview Table 133. ArQule Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. ArQule Inc Sickle Cell Disease Drug Product Portfolio Table 135. ArQule Inc Recent Development Table 136. Annexin Pharmaceuticals AB Company Information Table 137. Annexin Pharmaceuticals AB Business Overview Table 138. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolio Table 140. Annexin Pharmaceuticals AB Recent Development Table 141. Angiocrine Bioscience Inc Company Information Table 142. Angiocrine Bioscience Inc Business Overview Table 143. Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolio Table 145. Angiocrine Bioscience Inc Recent Development Table 146. Addmedica SAS Company Information Table 147. Addmedica SAS Business Overview Table 148. Addmedica SAS Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Addmedica SAS Sickle Cell Disease Drug Product Portfolio Table 150. Addmedica SAS Recent Development Table 151. Acceleron Pharma Inc Company Information Table 152. Acceleron Pharma Inc Business Overview Table 153. Acceleron Pharma Inc Sickle Cell Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolio Table 155. Acceleron Pharma Inc Recent Development Table 156. North America Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 157. North America Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 158. North America Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units) Table 159. North America Sickle Cell Disease Drug Sales by Type (2027-2032) & (K Units) Table 160. North America Sickle Cell Disease Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 161. North America Sickle Cell Disease Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 162. North America Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 163. North America Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 164. North America Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units) Table 165. North America Sickle Cell Disease Drug Sales by Application (2027-2032) & (K Units) Table 166. North America Sickle Cell Disease Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 167. North America Sickle Cell Disease Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 168. North America Sickle Cell Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. North America Sickle Cell Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 170. North America Sickle Cell Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 171. North America Sickle Cell Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 172. North America Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units) Table 173. North America Sickle Cell Disease Drug Sales by Country (2027-2032) & (K Units) Table 174. North America Sickle Cell Disease Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 175. North America Sickle Cell Disease Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 176. United States Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 177. Canada Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 178. Europe Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 179. Europe Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 180. Europe Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units) Table 181. Europe Sickle Cell Disease Drug Sales by Type (2027-2032) & (K Units) Table 182. Europe Sickle Cell Disease Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 183. Europe Sickle Cell Disease Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 184. Europe Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 185. Europe Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 186. Europe Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units) Table 187. Europe Sickle Cell Disease Drug Sales by Application (2027-2032) & (K Units) Table 188. Europe Sickle Cell Disease Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 189. Europe Sickle Cell Disease Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 190. Europe Sickle Cell Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 191. Europe Sickle Cell Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 192. Europe Sickle Cell Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 193. Europe Sickle Cell Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 194. Europe Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units) Table 195. Europe Sickle Cell Disease Drug Sales by Country (2027-2032) & (K Units) Table 196. Europe Sickle Cell Disease Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 197. Europe Sickle Cell Disease Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 198. Germany Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 199. France Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 200. U.K. Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 201. Italy Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 202. Netherlands Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 203. China Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 204. China Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 205. China Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units) Table 206. China Sickle Cell Disease Drug Sales by Type (2027-2032) & (K Units) Table 207. China Sickle Cell Disease Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 208. China Sickle Cell Disease Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 209. China Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 210. China Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 211. China Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units) Table 212. China Sickle Cell Disease Drug Sales by Application (2027-2032) & (K Units) Table 213. China Sickle Cell Disease Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 214. China Sickle Cell Disease Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 215. Asia Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 216. Asia Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 217. Asia Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units) Table 218. Asia Sickle Cell Disease Drug Sales by Type (2027-2032) & (K Units) Table 219. Asia Sickle Cell Disease Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 220. Asia Sickle Cell Disease Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 221. Asia Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 222. Asia Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 223. Asia Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units) Table 224. Asia Sickle Cell Disease Drug Sales by Application (2027-2032) & (K Units) Table 225. Asia Sickle Cell Disease Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 226. Asia Sickle Cell Disease Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 227. Asia Sickle Cell Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 228. Asia Sickle Cell Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 229. Asia Sickle Cell Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 230. Asia Sickle Cell Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 231. Asia Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units) Table 232. Asia Sickle Cell Disease Drug Sales by Country (2027-2032) & (K Units) Table 233. Asia Sickle Cell Disease Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 234. Asia Sickle Cell Disease Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 235. Japan Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 236. South Korea Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 237. India Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 238. Australia Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 239. China Taiwan Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 240. Southeast Asia Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 241. SAMEA Sickle Cell Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 242. SAMEA Sickle Cell Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 243. SAMEA Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units) Table 244. SAMEA Sickle Cell Disease Drug Sales by Type (2027-2032) & (K Units) Table 245. SAMEA Sickle Cell Disease Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 246. SAMEA Sickle Cell Disease Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 247. SAMEA Sickle Cell Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 248. SAMEA Sickle Cell Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 249. SAMEA Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units) Table 250. SAMEA Sickle Cell Disease Drug Sales by Application (2027-2032) & (K Units) Table 251. SAMEA Sickle Cell Disease Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 252. SAMEA Sickle Cell Disease Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 253. SAMEA Sickle Cell Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 254. SAMEA Sickle Cell Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 255. SAMEA Sickle Cell Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 256. SAMEA Sickle Cell Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 257. SAMEA Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units) Table 258. SAMEA Sickle Cell Disease Drug Sales by Country (2027-2032) & (K Units) Table 259. SAMEA Sickle Cell Disease Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 260. SAMEA Sickle Cell Disease Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 261. Brazil Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 262. Argentina Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 263. Chile Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 264. Colombia Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 265. Peru Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 266. Saudi Arabia Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 267. Israel Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 268. UAE Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 269. Turkey Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 270. Iran Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 271. Egypt Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Table 272. Key Raw Materials Table 273. Raw Materials Key Suppliers Table 274. Sickle Cell Disease Drug Distributors List Table 275. Sickle Cell Disease Drug Customers List Table 276. Research Programs/Design for This Report Table 277. Authors List of This Report Table 278. Secondary Sources Table 279. Primary Sources List of Figures Figure 1. Sickle Cell Disease Drug Image Figure 2. Global Sickle Cell Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sickle Cell Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. CAL-H Image Figure 5. DRX-194 Image Figure 6. CTX-001 Image Figure 7. BIVV-003 Image Figure 8. ARQ-092 Image Figure 9. Others Image Figure 10. Global Sickle Cell Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Sickle Cell Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Sickle Cell Disease Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million) Figure 17. Global Sickle Cell Disease Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Sickle Cell Disease Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Sickle Cell Disease Drug Revenue Market Share by Region (2021-2032) Figure 20. Global Sickle Cell Disease Drug Sales (2021-2032) & (K Units) Figure 21. Global Sickle Cell Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global Sickle Cell Disease Drug Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Sickle Cell Disease Drug Sales YoY (2021-2032) & (K Units) Figure 24. Europe Sickle Cell Disease Drug Sales YoY (2021-2032) & (K Units) Figure 25. China Sickle Cell Disease Drug Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) Sickle Cell Disease Drug Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa Sickle Cell Disease Drug Sales YoY (2021-2032) & (K Units) Figure 28. Global Sickle Cell Disease Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Sickle Cell Disease Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Sickle Cell Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Sickle Cell Disease Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Sickle Cell Disease Drug Revenue Market Share by Type (2021-2032) Figure 34. Global Sickle Cell Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global Sickle Cell Disease Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Sickle Cell Disease Drug Sales Market Share by Type (2021-2032) Figure 37. Global Sickle Cell Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Sickle Cell Disease Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Sickle Cell Disease Drug Revenue Market Share by Application (2021-2032) Figure 40. Global Sickle Cell Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global Sickle Cell Disease Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Sickle Cell Disease Drug Sales Market Share by Application (2021-2032) Figure 43. North America Sickle Cell Disease Drug Revenue Share by Type (2021-2032) Figure 44. North America Sickle Cell Disease Drug Sales Share by Type (2021-2032) Figure 45. North America Sickle Cell Disease Drug Revenue Share by Application (2021-2032) Figure 46. North America Sickle Cell Disease Drug Sales Share by Application (2021-2032) Figure 47. North America Sickle Cell Disease Drug Revenue Share by Country (2021-2032) Figure 48. North America Sickle Cell Disease Drug Sales Share by Country (2021-2032) Figure 49. Europe Sickle Cell Disease Drug Revenue Share by Type (2021-2032) Figure 50. Europe Sickle Cell Disease Drug Sales Share by Type (2021-2032) Figure 51. Europe Sickle Cell Disease Drug Revenue Share by Application (2021-2032) Figure 52. Europe Sickle Cell Disease Drug Sales Share by Application (2021-2032) Figure 53. Europe Sickle Cell Disease Drug Revenue Share by Country (2021-2032) Figure 54. Europe Sickle Cell Disease Drug Sales Share by Country (2021-2032) Figure 55. China Sickle Cell Disease Drug Revenue Share by Type (2021-2032) Figure 56. China Sickle Cell Disease Drug Sales Share by Type (2021-2032) Figure 57. China Sickle Cell Disease Drug Revenue Share by Application (2021-2032) Figure 58. China Sickle Cell Disease Drug Sales Share by Application (2021-2032) Figure 59. Asia Sickle Cell Disease Drug Revenue Share by Type (2021-2032) Figure 60. Asia Sickle Cell Disease Drug Sales Share by Type (2021-2032) Figure 61. Asia Sickle Cell Disease Drug Revenue Share by Application (2021-2032) Figure 62. Asia Sickle Cell Disease Drug Sales Share by Application (2021-2032) Figure 63. Asia Sickle Cell Disease Drug Revenue Share by Country (2021-2032) Figure 64. Asia Sickle Cell Disease Drug Sales Share by Country (2021-2032) Figure 65. SAMEA Sickle Cell Disease Drug Revenue Share by Type (2021-2032) Figure 66. SAMEA Sickle Cell Disease Drug Sales Share by Type (2021-2032) Figure 67. SAMEA Sickle Cell Disease Drug Revenue Share by Application (2021-2032) Figure 68. SAMEA Sickle Cell Disease Drug Sales Share by Application (2021-2032) Figure 69. SAMEA Sickle Cell Disease Drug Revenue Share by Country (2021-2032) Figure 70. SAMEA Sickle Cell Disease Drug Sales Share by Country (2021-2032) Figure 71. Sickle Cell Disease Drug Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Sickle Cell Disease Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • CAL-H
  • DRX-194
  • CTX-001
  • BIVV-003
  • ARQ-092
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Global Blood Therapeutics Inc
  • Gilead Sciences Inc
  • Genethon SA
  • Gamida Cell Ltd
  • Errant Gene Therapeutics LLC
  • Editas Medicine Inc
  • Daiichi Sankyo Co Ltd
  • CSL Ltd
  • CRISPR Therapeutics
  • Calimmune Inc
  • Bristol-Myers Squibb Co
  • bluebird bio Inc
  • Bioverativ Inc
  • Bio Products Laboratory Ltd
  • ArQule Inc
  • Annexin Pharmaceuticals AB
  • Angiocrine Bioscience Inc
  • Addmedica SAS
  • Acceleron Pharma Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Sickle Cell Disease Drug Market by Type
  3. 1.2.1 Global Sickle Cell Disease Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CAL-H
  5. 1.2.3 DRX-194
  6. 1.2.4 CTX-001
  7. 1.2.5 BIVV-003
  8. 1.2.6 ARQ-092
  9. 1.2.7 Others
  10. 1.3 Sickle Cell Disease Drug Market by Application
  11. 1.3.1 Global Sickle Cell Disease Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital
  13. 1.3.3 Clinic
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Sickle Cell Disease Drug Market Dynamics
  1. 2.1 Sickle Cell Disease Drug Industry Trends
  2. 2.2 Sickle Cell Disease Drug Industry Drivers
  3. 2.3 Sickle Cell Disease Drug Industry Opportunities and Challenges
  4. 2.4 Sickle Cell Disease Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Sickle Cell Disease Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Sickle Cell Disease Drug Revenue by Region
  3. 3.2.1 Global Sickle Cell Disease Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Sickle Cell Disease Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Sickle Cell Disease Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Sickle Cell Disease Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Sickle Cell Disease Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Sickle Cell Disease Drug Sales by Region
  9. 3.4.1 Global Sickle Cell Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Sickle Cell Disease Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Sickle Cell Disease Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Sickle Cell Disease Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Sickle Cell Disease Drug Revenue by Manufacturers
  2. 4.1.1 Global Sickle Cell Disease Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Sickle Cell Disease Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Sickle Cell Disease Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Sickle Cell Disease Drug Sales by Manufacturers
  6. 4.2.1 Global Sickle Cell Disease Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Sickle Cell Disease Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Sickle Cell Disease Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Sickle Cell Disease Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Sickle Cell Disease Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Sickle Cell Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Sickle Cell Disease Drug Manufacturers, Product Type & Application
  13. 4.7 Global Sickle Cell Disease Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Sickle Cell Disease Drug Market CR5 and HHI
  16. 4.8.2 2025 Sickle Cell Disease Drug Tier 1, Tier 2, and Tier 3
5 Sickle Cell Disease Drug Market by Type
  1. 5.1 Global Sickle Cell Disease Drug Revenue by Type
  2. 5.1.1 Global Sickle Cell Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Sickle Cell Disease Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Sickle Cell Disease Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Sickle Cell Disease Drug Sales by Type
  6. 5.2.1 Global Sickle Cell Disease Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Sickle Cell Disease Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Sickle Cell Disease Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Sickle Cell Disease Drug Price by Type
6 Sickle Cell Disease Drug Market by Application
  1. 6.1 Global Sickle Cell Disease Drug Revenue by Application
  2. 6.1.1 Global Sickle Cell Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Sickle Cell Disease Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Sickle Cell Disease Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Sickle Cell Disease Drug Sales by Application
  6. 6.2.1 Global Sickle Cell Disease Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Sickle Cell Disease Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Sickle Cell Disease Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Sickle Cell Disease Drug Price by Application
7 Company Profiles
  1. 7.1 Global Blood Therapeutics Inc
  2. 7.1.1 Global Blood Therapeutics Inc Company Information
  3. 7.1.2 Global Blood Therapeutics Inc Business Overview
  4. 7.1.3 Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolio
  6. 7.1.5 Global Blood Therapeutics Inc Recent Developments
  7. 7.2 Gilead Sciences Inc
  8. 7.2.1 Gilead Sciences Inc Company Information
  9. 7.2.2 Gilead Sciences Inc Business Overview
  10. 7.2.3 Gilead Sciences Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolio
  12. 7.2.5 Gilead Sciences Inc Recent Developments
  13. 7.3 Genethon SA
  14. 7.3.1 Genethon SA Company Information
  15. 7.3.2 Genethon SA Business Overview
  16. 7.3.3 Genethon SA Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Genethon SA Sickle Cell Disease Drug Product Portfolio
  18. 7.3.5 Genethon SA Recent Developments
  19. 7.4 Gamida Cell Ltd
  20. 7.4.1 Gamida Cell Ltd Company Information
  21. 7.4.2 Gamida Cell Ltd Business Overview
  22. 7.4.3 Gamida Cell Ltd Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolio
  24. 7.4.5 Gamida Cell Ltd Recent Developments
  25. 7.5 Errant Gene Therapeutics LLC
  26. 7.5.1 Errant Gene Therapeutics LLC Company Information
  27. 7.5.2 Errant Gene Therapeutics LLC Business Overview
  28. 7.5.3 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolio
  30. 7.5.5 Errant Gene Therapeutics LLC Recent Developments
  31. 7.6 Editas Medicine Inc
  32. 7.6.1 Editas Medicine Inc Company Information
  33. 7.6.2 Editas Medicine Inc Business Overview
  34. 7.6.3 Editas Medicine Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Editas Medicine Inc Sickle Cell Disease Drug Product Portfolio
  36. 7.6.5 Editas Medicine Inc Recent Developments
  37. 7.7 Daiichi Sankyo Co Ltd
  38. 7.7.1 Daiichi Sankyo Co Ltd Company Information
  39. 7.7.2 Daiichi Sankyo Co Ltd Business Overview
  40. 7.7.3 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolio
  42. 7.7.5 Daiichi Sankyo Co Ltd Recent Developments
  43. 7.8 CSL Ltd
  44. 7.8.1 CSL Ltd Company Information
  45. 7.8.2 CSL Ltd Business Overview
  46. 7.8.3 CSL Ltd Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 CSL Ltd Sickle Cell Disease Drug Product Portfolio
  48. 7.8.5 CSL Ltd Recent Developments
  49. 7.9 CRISPR Therapeutics
  50. 7.9.1 CRISPR Therapeutics Company Information
  51. 7.9.2 CRISPR Therapeutics Business Overview
  52. 7.9.3 CRISPR Therapeutics Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolio
  54. 7.9.5 CRISPR Therapeutics Recent Developments
  55. 7.10 Calimmune Inc
  56. 7.10.1 Calimmune Inc Company Information
  57. 7.10.2 Calimmune Inc Business Overview
  58. 7.10.3 Calimmune Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Calimmune Inc Sickle Cell Disease Drug Product Portfolio
  60. 7.10.5 Calimmune Inc Recent Developments
  61. 7.11 Bristol-Myers Squibb Co
  62. 7.11.1 Bristol-Myers Squibb Co Company Information
  63. 7.11.2 Bristol-Myers Squibb Co Business Overview
  64. 7.11.3 Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolio
  66. 7.11.5 Bristol-Myers Squibb Co Recent Developments
  67. 7.12 bluebird bio Inc
  68. 7.12.1 bluebird bio Inc Company Information
  69. 7.12.2 bluebird bio Inc Business Overview
  70. 7.12.3 bluebird bio Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 bluebird bio Inc Sickle Cell Disease Drug Product Portfolio
  72. 7.12.5 bluebird bio Inc Recent Developments
  73. 7.13 Bioverativ Inc
  74. 7.13.1 Bioverativ Inc Company Information
  75. 7.13.2 Bioverativ Inc Business Overview
  76. 7.13.3 Bioverativ Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Bioverativ Inc Sickle Cell Disease Drug Product Portfolio
  78. 7.13.5 Bioverativ Inc Recent Developments
  79. 7.14 Bio Products Laboratory Ltd
  80. 7.14.1 Bio Products Laboratory Ltd Company Information
  81. 7.14.2 Bio Products Laboratory Ltd Business Overview
  82. 7.14.3 Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolio
  84. 7.14.5 Bio Products Laboratory Ltd Recent Developments
  85. 7.15 ArQule Inc
  86. 7.15.1 ArQule Inc Company Information
  87. 7.15.2 ArQule Inc Business Overview
  88. 7.15.3 ArQule Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 ArQule Inc Sickle Cell Disease Drug Product Portfolio
  90. 7.15.5 ArQule Inc Recent Developments
  91. 7.16 Annexin Pharmaceuticals AB
  92. 7.16.1 Annexin Pharmaceuticals AB Company Information
  93. 7.16.2 Annexin Pharmaceuticals AB Business Overview
  94. 7.16.3 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolio
  96. 7.16.5 Annexin Pharmaceuticals AB Recent Developments
  97. 7.17 Angiocrine Bioscience Inc
  98. 7.17.1 Angiocrine Bioscience Inc Company Information
  99. 7.17.2 Angiocrine Bioscience Inc Business Overview
  100. 7.17.3 Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolio
  102. 7.17.5 Angiocrine Bioscience Inc Recent Developments
  103. 7.18 Addmedica SAS
  104. 7.18.1 Addmedica SAS Company Information
  105. 7.18.2 Addmedica SAS Business Overview
  106. 7.18.3 Addmedica SAS Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Addmedica SAS Sickle Cell Disease Drug Product Portfolio
  108. 7.18.5 Addmedica SAS Recent Developments
  109. 7.19 Acceleron Pharma Inc
  110. 7.19.1 Acceleron Pharma Inc Company Information
  111. 7.19.2 Acceleron Pharma Inc Business Overview
  112. 7.19.3 Acceleron Pharma Inc Sickle Cell Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolio
  114. 7.19.5 Acceleron Pharma Inc Recent Developments
8 North America
  1. 8.1 North America Sickle Cell Disease Drug Market Size by Type
  2. 8.1.1 North America Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Sickle Cell Disease Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Sickle Cell Disease Drug Price by Type (2021-2032)
  5. 8.2 North America Sickle Cell Disease Drug Market Size by Application
  6. 8.2.1 North America Sickle Cell Disease Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Sickle Cell Disease Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Sickle Cell Disease Drug Price by Application (2021-2032)
  9. 8.3 North America Sickle Cell Disease Drug Market Size by Country
  10. 8.3.1 North America Sickle Cell Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Sickle Cell Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Sickle Cell Disease Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Sickle Cell Disease Drug Market Size by Type
  2. 9.1.1 Europe Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Sickle Cell Disease Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Sickle Cell Disease Drug Price by Type (2021-2032)
  5. 9.2 Europe Sickle Cell Disease Drug Market Size by Application
  6. 9.2.1 Europe Sickle Cell Disease Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Sickle Cell Disease Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Sickle Cell Disease Drug Price by Application (2021-2032)
  9. 9.3 Europe Sickle Cell Disease Drug Market Size by Country
  10. 9.3.1 Europe Sickle Cell Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Sickle Cell Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Sickle Cell Disease Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Sickle Cell Disease Drug Market Size by Type
  2. 10.1.1 China Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Sickle Cell Disease Drug Sales by Type (2021-2032)
  4. 10.1.3 China Sickle Cell Disease Drug Price by Type (2021-2032)
  5. 10.2 China Sickle Cell Disease Drug Market Size by Application
  6. 10.2.1 China Sickle Cell Disease Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Sickle Cell Disease Drug Sales by Application (2021-2032)
  8. 10.2.3 China Sickle Cell Disease Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Sickle Cell Disease Drug Market Size by Type
  2. 11.1.1 Asia Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Sickle Cell Disease Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Sickle Cell Disease Drug Price by Type (2021-2032)
  5. 11.2 Asia Sickle Cell Disease Drug Market Size by Application
  6. 11.2.1 Asia Sickle Cell Disease Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Sickle Cell Disease Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Sickle Cell Disease Drug Price by Application (2021-2032)
  9. 11.3 Asia Sickle Cell Disease Drug Market Size by Country
  10. 11.3.1 Asia Sickle Cell Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Sickle Cell Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Sickle Cell Disease Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Sickle Cell Disease Drug Market Size by Type
  2. 12.1.1 SAMEA Sickle Cell Disease Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Sickle Cell Disease Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Sickle Cell Disease Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Sickle Cell Disease Drug Market Size by Application
  6. 12.2.1 SAMEA Sickle Cell Disease Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Sickle Cell Disease Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Sickle Cell Disease Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Sickle Cell Disease Drug Market Size by Country
  10. 12.3.1 SAMEA Sickle Cell Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Sickle Cell Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Sickle Cell Disease Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Sickle Cell Disease Drug Value Chain Analysis
  2. 13.1.1 Sickle Cell Disease Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Sickle Cell Disease Drug Production Mode & Process
  6. 13.2 Sickle Cell Disease Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Sickle Cell Disease Drug Distributors
  9. 13.2.3 Sickle Cell Disease Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst